FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Dec. 24, 2003--SoLar Pharmaceuticals, Inc. ("SoLar") announced today the election of Martin Zeiger, Esq., and David Lucking to its Board of Directors. Mr. Zeiger joins Elliot F. Hahn, Ph.D. and Nigel N. Norton as a non-employee Executive Director, and Mr. Lucking joins Lawrence Solomon, M.D. as an employee, non-executive director.
Following a career involving extensive service in senior legal and management positions in different segments of the pharmaceutical industry, Mr. Zeiger resigned his post as Senior Vice-President of Barr Laboratories, Inc. (NYSE:BRL) in August, 2003, in order to begin his own consulting firm in New York City.
Mr. Zeiger, 66, was Publications Editor of the Law Review at St. Johns University School of Law in New York City, from which he graduated in 1960. He then obtained governmental and private experience practicing law from 1960 until 1965. In 1965, he joined J.C. Penney & Company as Counsel for Labor Relations and the Drug Store Division, and in 1972, became Vice President, General Counsel, and Corporate Secretary for Jack Eckerd Corp. Subsequently, he served from 1975-1986 as Senior Vice President of Administration and General Counsel for Revco Drug Stores, Inc. In 1987, he joined Rugby Laboratories, Inc. as Executive Vice President for Administration and General Counsel, where he was the Chief Administrative and Legal Officer. Rugby was acquired by Marion Merrill Dow, Inc. (MMD) in 1993, which in turn was acquired by Hoechst in 1995, forming Hoechst Marion Roussel, Inc. (HMR). Mr. Zeiger continued as Vice President for both MMD and HMR, with involvement in general business matters, generic drug opportunities, and government affairs. In 2000, he joined Barr as Senior Vice President for Strategic Business Development and General Counsel.
In addition, Mr. Zeiger is a Director and Member of the Audit Committee of Vasomedical, Inc. (NASDAQ:VASO), a cardiovascular device company. He is a Member of the Heritage Board of Directors of the American Heart Association and is also a Founding Director and Member of the Board of Governors of the Larry King Cardiac Foundation.
Mr. Lucking joined SoLar in March of 2003, and is its Executive Vice President and Chief Operating Officer. He has substantial experience with pharmaceutical firms in South Florida, most recently having had a variety of senior executive positions at Noven Pharmaceuticals, Inc (NASDAQ:NOVN), from its inception in 1987 to 2003. At Noven, Mr. Lucking was extensively involved in conducting pre-clinical and clinical studies, coordinating with the FDA and European pharmaceutical regulatory agencies, and participating in bringing products from the concept stage to final FDA approval. Previous to joining Noven, he was employed by Key Pharmaceuticals, Inc. He also is a director of SFBC International (NASDAQ:SFCC), a Miami-based contract research organization.
Lawrence Solomon, M.D., President and Chief Executive Officer of SoLar, stated: "SoLar is proud to have professionals of the quality of Marty and David join its Board. We are especially honored that, with no lack of opportunities after leaving Barr, Marty has elected to serve as an Executive Director. His addition represents a material enhancement of SoLar's capabilities. We look forward to a long and fruitful relationship."
Incorporated in 2001, SoLar Pharmaceuticals, Inc. is a development stage pharmaceutical firm with interests focused on the cardiovascular field.
SoLar is located at 5310 N.W. 33rd Ave., Suite 118, Ft. Lauderdale, FL 33309. Contact Ann Hasen for further corporate information at (954) 535-9150 ext. 100, or at A.Hasen@solarpharm.com.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," " plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the timing and outcome of litigation and future product launches; government regulation generally; competition; manufacturing capacities and output; commercial obstacles to the successful introduction of brand products generally; product liability claims; rising costs and availability of insurance, including product liability insurance; and the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals. SoLar Pharmaceuticals, Inc. disclaims any responsibility to update the statements contained herein.
SoLar Pharmaceuticals, Inc., Fort Lauderdale
Ann Hasen, 954/535-9150 ext. 100